Erleada and Lopinavir and ritonavir
Determining the interaction of Erleada and Lopinavir and ritonavir and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.CONTRAINDICATED: Coadministration with apalutamide may decrease the plasma concentrations of ritonavir and result in a potential loss of virologic response. The proposed mechanism is increased clearance due to apalutamide-mediated induction of CYP450 3A4, which is the isoenzyme primarily responsible for the metabolism of ritonavir. In addition, concomitant use of ritonavir may increase the plasma levels of apalutamide and risk of adverse effects, including seizures and fracture. The proposed mechanism is ritonavir-mediated inhibition of CYP450 3A4. MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of ritonavir with apalutamide is considered contraindicated. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 Cerner Multum, Inc. "Australian Product Information." O 0 Cerner Multum, Inc. "Canadian Product Information." O 0 (2015): "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL. View all 4 references
Professional:CONTRAINDICATED: Coadministration with apalutamide may decrease the plasma concentrations of ritonavir and result in a potential loss of virologic response. The proposed mechanism is increased clearance due to apalutamide-mediated induction of CYP450 3A4, which is the isoenzyme primarily responsible for the metabolism of ritonavir. In addition, concomitant use of ritonavir may increase the plasma levels of apalutamide and risk of adverse effects, including seizures and fracture. The proposed mechanism is ritonavir-mediated inhibition of CYP450 3A4.
MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of ritonavir with apalutamide is considered contraindicated.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
- "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.
Generic Name: lopinavir / ritonavir
Brand name: Kaletra
Synonyms: Lopinavir and Ritonavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Erleada-Lopinavir and Ritonavir Oral Solution
- Erleada-Lopinavir and Ritonavir Solution
- Erleada-Lopinavir and Ritonavir Tablets
- Erleada-Lopreeza
- Erleada-Lopressor
- Erleada-Lopressor (Metoprolol Injection)
- Lopinavir and ritonavir-Erlotinib
- Lopinavir and ritonavir-Erlotinib Tablets
- Lopinavir and ritonavir-Errin
- Lopinavir and ritonavir-Ertapenem
- Lopinavir and ritonavir-Ertapenem Injection
- Lopinavir and ritonavir-Ertapenem Sodium